Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 286

1.

Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: a report from the National Cardiovascular Data Registry.

Kutcher MA, Brennan JM, Rao SV, Dai D, Anstrom KJ, Mustafa N, Sedrakyan A, Booth ME, Douglas PS, Messenger JC.

Catheter Cardiovasc Interv. 2014 Feb;83(2):171-81. doi: 10.1002/ccd.25108. Epub 2013 Aug 31. Erratum in: Catheter Cardiovasc Interv. 2014 Jul 1;84(1):168. Sedrakayan, Art [corrected to Sedrakyan].

PMID:
23907981
2.

Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.

Richardt G, Leschke M, Abdel-Wahab M, Toelg R, El-Mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann FJ, Widimsky P; RESOLUTE All Comers.; RESOLUTE International Investigators..

JACC Cardiovasc Interv. 2013 Sep;6(9):905-13. doi: 10.1016/j.jcin.2013.04.017. Epub 2013 Aug 14.

3.

Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.

Puymirat E, Mangiacapra F, Peace A, Ntarladimas Y, Conte M, Bartunek J, Vanderheyden M, Wijns W, de Bruyne B, Barbato E.

Arch Cardiovasc Dis. 2013 Nov;106(11):554-61. doi: 10.1016/j.acvd.2013.06.056. Epub 2013 Nov 11.

4.

Comparative effectiveness of drug-eluting versus bare-metal stents in elderly patients undergoing revascularization of chronic total coronary occlusions: results from the National Cardiovascular Data Registry, 2005-2008.

Patel MR, Marso SP, Dai D, Anstrom KJ, Shunk KA, Curtus JP, Brennan JM, Sedrakyan A, Messenger JC, Douglas PS.

JACC Cardiovasc Interv. 2012 Oct;5(10):1054-61. doi: 10.1016/j.jcin.2012.05.017.

5.

Outcomes of small coronary artery stenting with bare-metal stents versus drug-eluting stents: results from the NHLBI Dynamic Registry.

Parikh SV, Luna M, Selzer F, Marroquin OC, Mulukutla SR, Abbott JD, Holper EM.

Catheter Cardiovasc Interv. 2014 Feb;83(2):192-200. doi: 10.1002/ccd.23194. Epub 2013 Oct 24.

6.

Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.

Kufner S, Cassese S, Valeskini M, Neumann FJ, Schulz-Sch├╝pke S, Hoppmann P, Fusaro M, Schunkert H, Laugwitz KL, Kastrati A, Byrne RA; ISAR-DESIRE 3 Investigators..

JACC Cardiovasc Interv. 2015 Jun;8(7):877-84. doi: 10.1016/j.jcin.2015.01.031. Epub 2015 May 20.

7.

Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.

Naganuma T, Chieffo A, Meliga E, Capodanno D, Park SJ, Onuma Y, Valgimigli M, Jegere S, Makkar RR, Palacios IF, Costopoulos C, Kim YH, Buszman PP, Chakravarty T, Sheiban I, Mehran R, Naber C, Margey R, Agnihotri A, Marra S, Capranzano P, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri O, Serruys PW, Colombo A.

JACC Cardiovasc Interv. 2013 Dec;6(12):1242-9. doi: 10.1016/j.jcin.2013.08.005.

8.

In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.

Tolerico PH, Cohen DJ, Kleiman NS, Berger PB, Brilakis ES, Piana RN, Shammo S, Keyes MJ, Kennedy KF, Massaro JM, Saucedo JF; EVENT Investigators..

Catheter Cardiovasc Interv. 2012 Dec 1;80(7):1127-36. doi: 10.1002/ccd.24352. Epub 2012 May 4.

PMID:
22431166
9.

Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).

Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators..

JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008. Epub 2013 Dec 11.

10.

In-hospital and one year outcomes with drug-eluting versus bare metal stents in large native coronary arteries: a report from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.

Gordon PC, Cohen DJ, Kleiman NS, Montgomery JA, Semder CA, Kennedy KF, Keyes MJ, Piana RN; EVENT Investigators..

Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E356-64. doi: 10.1002/ccd.24451. Epub 2013 May 25.

PMID:
22511502
11.

Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis.

Singh IM, Filby SJ, El Sakr F, Gorodeski EZ, Lincoff AM, Ellis SG, Shishehbor MH.

Catheter Cardiovasc Interv. 2010 Aug 1;76(2):257-62. doi: 10.1002/ccd.22509.

12.

Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.

Brodie BR, Wilson H, Stuckey T, Nussbaum M, Laurent S, Bradshaw B, Humphrey A, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Simonton CA; STENT Group..

JACC Cardiovasc Interv. 2009 Nov;2(11):1105-12. doi: 10.1016/j.jcin.2009.08.020.

13.

Clinical and procedural predictors of suboptimal outcome after the treatment of drug-eluting stent restenosis in the unprotected distal left main stem: the Milan and New-Tokyo (MITO) registry.

Takagi K, Ielasi A, Shannon J, Latib A, Godino C, Davidavicius G, Mussardo M, Ferrarello S, Figini F, Carlino M, Montorfano M, Chieffo A, Nakamura S, Colombo A.

Circ Cardiovasc Interv. 2012 Aug 1;5(4):491-8. doi: 10.1161/CIRCINTERVENTIONS.111.964874. Epub 2012 Jul 31.

14.

Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.

Rodriguez AE, Rodriguez-Granillo AM, Antoniucci D, Mieres J, Fernandez-Pereira C, Rodriguez-Granillo GA, Santaera O, Rubilar B, Palacios IF, Serruys PW; ORAR III Investigators..

Catheter Cardiovasc Interv. 2012 Sep 1;80(3):385-94. doi: 10.1002/ccd.23352. Epub 2011 Dec 8.

PMID:
22109997
15.

Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.

Moscarella E, Ielasi A, Granata F, Coscarelli S, Stabile E, Latib A, Cortese B, Tespili M, Tanaka A, Capozzolo C, Caliendo L, Colombo A, Varricchio A.

Circ Cardiovasc Interv. 2016 Apr;9(4):e003148. doi: 10.1161/CIRCINTERVENTIONS.115.003148.

16.

Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).

Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.

JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005.

17.

Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.

Jones DA, Rathod KS, Gallagher S, Weerackody R, Knight CJ, Rothman MT, Mathur A, Jain AK, Timmis AD, Wragg A.

Catheter Cardiovasc Interv. 2013 May;81(6):E237-44. doi: 10.1002/ccd.24513. Epub 2012 Nov 14.

PMID:
22707383
18.

The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.

Alsidawi S, Effat M, Rahman S, Abdallah M, Leesar M.

Cardiovasc Ther. 2015 Dec;33(6):360-6. doi: 10.1111/1755-5922.12160. Review.

PMID:
26363283
19.

Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations.

Magalhaes MA, Minha S, Chen F, Torguson R, Omar AF, Loh JP, Escarcega RO, Lipinski MJ, Baker NC, Kitabata H, Ota H, Suddath WO, Satler LF, Pichard AD, Waksman R.

Circ Cardiovasc Interv. 2014 Dec;7(6):768-76. doi: 10.1161/CIRCINTERVENTIONS.114.001341. Epub 2014 Dec 2.

20.

Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.

Onuma Y, Kukreja N, Daemen J, Garcia-Garcia HM, Gonzalo N, Cheng JM, van Twisk PH, van Domburg R, Serruys PW; Interventional Cardiologists of Thoraxcenter..

JACC Cardiovasc Interv. 2009 Jul;2(7):603-10. doi: 10.1016/j.jcin.2009.03.016.

Supplemental Content

Support Center